The Mesoblast (ASX: MSB) share price rose 6.67% on Friday, 10 July 2026, gaining 14 cents to close at A$2.24. The stock also gained approximately 9.3% across the week, making it one of the stronger performers in the S&P/ASX 200.
The rise came after Mesoblast reported preliminary Ryoncil net revenue of US$36 million for the fourth quarter and US$115 million for the full financial year ended 30 June 2026.
Why Did Mesoblast Shares Rise?
The company’s Ryoncil revenue update was the clearest reason for Friday’s share price gain.
Mesoblast said the treatment had experienced strong uptake since its commercial launch. Chief executive Dr Silviu Itescu also said revenue had already exceeded the company’s initial projections.
For investors, the result provides early evidence that Ryoncil is generating meaningful commercial sales. This is particularly important for a biotechnology company, as developing and gaining approval for a new treatment can take many years and require significant investment.
Mesoblast expects Ryoncil revenue to continue growing during the new financial year. However, this is a company expectation rather than a guaranteed result.
What Is Ryoncil?
Ryoncil, also known as remestemcel-L-rknd, is a cell therapy used to treat steroid-refractory acute graft-versus-host disease, or SR-aGvHD, in children aged two months and older.
Acute graft-versus-host disease can develop after a patient receives a stem-cell or bone-marrow transplant from a donor. It happens when the donated immune cells attack the patient’s healthy tissue.
“Steroid-refractory” means the disease has not responded adequately to steroid treatment.
Ryoncil is the first mesenchymal stromal cell therapy approved by the US Food and Drug Administration for any condition. It is also the only FDA-approved treatment for SR-aGvHD in children younger than 12.
Why Does the Revenue Update Matter?
Many biotechnology companies remain unprofitable while they develop treatments and complete clinical trials. A successful commercial product can therefore represent an important turning point.
Ryoncil’s US$115 million in preliminary full-year net revenue shows that Mesoblast is moving beyond being mainly a drug-development business. Continued sales growth could provide more money to support operations and advance the company’s wider treatment pipeline.
However, investors should note that the announced revenue figures were preliminary. They remain subject to normal financial year-end closing and audit procedures.
Mesoblast is also working to expand Ryoncil into additional patient groups and medical conditions. These opportunities could support future growth, but they still involve clinical, commercial, and regulatory risks.
What Should Mesoblast Investors Watch Next?
Investors should watch whether Ryoncil sales continue growing across US treatment centres and whether Mesoblast can manage the costs involved in producing and selling the therapy.
Progress toward possible approvals for additional uses will also be important. Investors should monitor clinical trial results, regulatory updates, cash flow, and funding requirements.
Mesoblast’s 6.67% Friday gain shows that investors welcomed the latest revenue figures. Future performance, however, will depend on whether the company can maintain Ryoncil’s sales momentum and successfully develop the rest of its treatment pipeline.
